223 related articles for article (PubMed ID: 26135113)
1. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
den Hollander MW; Bensch F; Glaudemans AW; Oude Munnink TH; Enting RH; den Dunnen WF; Heesters MA; Kruyt FA; Lub-de Hooge MN; Cees de Groot J; Pearlberg J; Gietema JA; de Vries EG; Walenkamp AM
J Nucl Med; 2015 Sep; 56(9):1310-4. PubMed ID: 26135113
[TBL] [Abstract][Full Text] [Related]
2. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.
Oude Munnink TH; Arjaans ME; Timmer-Bosscha H; Schröder CP; Hesselink JW; Vedelaar SR; Walenkamp AM; Reiss M; Gregory RC; Lub-de Hooge MN; de Vries EG
J Nucl Med; 2011 Dec; 52(12):2001-8. PubMed ID: 22072706
[TBL] [Abstract][Full Text] [Related]
3. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
4. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
5. Molecular Drug Imaging:
Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL
J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855
[TBL] [Abstract][Full Text] [Related]
6. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
[TBL] [Abstract][Full Text] [Related]
7. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
8. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
[TBL] [Abstract][Full Text] [Related]
9. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
10. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.
Oosting SF; van Asselt SJ; Brouwers AH; Bongaerts AH; Steinberg JD; de Jong JR; Lub-de Hooge MN; van der Horst-Schrivers AN; Walenkamp AM; Hoving EW; Sluiter WJ; Zonnenberg BA; de Vries EG; Links TP
J Nucl Med; 2016 Aug; 57(8):1244-50. PubMed ID: 27173161
[TBL] [Abstract][Full Text] [Related]
11. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with
Matsuda M; Ishikawa E; Yamamoto T; Hatano K; Joraku A; Iizumi Y; Masuda Y; Nishiyama H; Matsumura A
J Neurooncol; 2018 Jul; 138(3):581-589. PubMed ID: 29524126
[TBL] [Abstract][Full Text] [Related]
12. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
13. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients.
Kobayashi K; Hirata K; Yamaguchi S; Manabe O; Terasaka S; Kobayashi H; Shiga T; Hattori N; Tanaka S; Kuge Y; Tamaki N
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1071-80. PubMed ID: 25852010
[TBL] [Abstract][Full Text] [Related]
15. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
[TBL] [Abstract][Full Text] [Related]
16. Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma.
Kamson DO; Mittal S; Robinette NL; Muzik O; Kupsky WJ; Barger GR; Juhász C
Neuro Oncol; 2014 Oct; 16(10):1373-83. PubMed ID: 24670609
[TBL] [Abstract][Full Text] [Related]
17. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.
Bisdas S; Ritz R; Bender B; Braun C; Pfannenberg C; Reimold M; Naegele T; Ernemann U
Invest Radiol; 2013 May; 48(5):295-301. PubMed ID: 23296081
[TBL] [Abstract][Full Text] [Related]
18. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R
Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
